Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
Titel:
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
Auteur:
Gligorov, Joseph Doval, Dinesh Bines, José Alba, Emilio Cortes, Paulo Pierga, Jean-Yves Gupta, Vineet Costa, Rômulo Srock, Stefanie de Ducla, Sabine Freudensprung, Ulrich Mustacchi, Giorgio